Newsroom
Shareholders of Humacyte, Inc. Encouraged to Take Action Before January 17, 2025
By KlickAnalytics Data Insights | December 31, 2024 08:01PM ET
Key Points
- Humacyte, Inc. investors who suffered losses urged to contact various law firms before January 17, 2025
- Class action lawsuits filed against Humacyte, Inc. for alleged securities law violations
- Investors have the opportunity to lead class action lawsuits against the company
- The lawsuits aim to recover damages for investors who purchased Humacyte securities between May 10, 2024, and October 17, 2024
- Shareholders advised to act promptly to potentially recover losses incurred due to securities fraud
Investors who have experienced losses on their investments in Humacyte, Inc. (NASDAQ:HUMA) have been urged to take action before January 17, 2025. Several law firms, including Levi & Korsinsky, Bronstein, Gewirtz & Grossman LLC, Pomerantz Law Firm, Kirby McInerney LLP, and The Schall Law Firm, have announced class action lawsuits against the company and certain officers.
Levi & Korsinsky, a New York-based law firm, is actively notifying shareholders of Humacyte, Inc. about the opportunity to participate in a class action lawsuit in relation to alleged violations of federal securities laws. Investors who wish to learn more about potential recovery under these laws are encouraged to contact Joseph E. Levi, Esq. before the January 17, 2025 deadline.
Bronstein, Gewirtz & Grossman LLC, another renowned law firm, has announced that investors with substantial losses in Humacyte, Inc. also have the opportunity to lead a class action lawsuit against the company and its officers. Similarly, Pomerantz Law Firm is reminding shareholders about a class action lawsuit filed against Humacyte, Inc. for violations of the Securities Exchange Act of 1934.
Kirby McInerney LLP is urging investors who acquired Humacyte, Inc. securities between May 10, 2024, and October 17, 2024, to inquire about their rights regarding the ongoing class action lawsuit. The law firm is reminding investors that they have until January 17, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The Schall Law Firm, based in Los Angeles, is also actively seeking investors who purchased Humacyte, Inc. securities between May 10, 2024, and October 17, 2024, for potential recovery of losses due to violations of securities laws. Investors are advised to contact the firm before the January 17, 2025 deadline to explore their options for participating in the class action lawsuit.
investors who have suffered losses on their investments in Humacyte, Inc. are being encouraged to take action before January 17, 2025, by contacting the various law firms involved in the class action lawsuits. These legal proceedings aim to recover damages for investors who purchased Humacyte securities during the defined class period, potentially holding the company accountable for alleged securities law violations.
For more information:
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same analytics engine that powers every screen on this platform — so what comes back is a number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
You ask
“How does NVDA usually trade through earnings?”
It calls
→ ka.options_expected_move(NVDA)
It answers
NVDA has averaged a 9.2% absolute move on the day after earnings and closed higher 67% of the time. Two in three reactions land between −4.2% and +16.3% — the distribution is skewed right, not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with